Phase IB study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors
ID Number 11-0946
Principal Investigator(s)Matthew Galsky
Department(s) or Division(s)
Hematology and Medical Oncology
Description
The purpose of this study is to find a safe dose of dovitinib that can be given together with gemcitabine plus cisplatin or carboplatin. The purpose is also to find out what effects (good and bad) gemcitabine, cisplatin, carboplatin and dovitinib have on you and your cancer. This study will evaluate if adding dovitinib to gemcitabine plus cisplatin or carboplatin will make those drugs work better in treating cancer. Dovitinib is considered an investigational drug. “Investigational” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). However, the FDA has allowed the use of this drug for research.
You may qualify to take part in this research study because you have advanced or metastatic cancer.
Contact Information
(212) 824-7343
(212) 824-7293
Recruiting Patients: Yes